Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market

Richard Quinn  |  March 17, 2015

Biosimilar drugs have the potential to reduce costs for patients with rheumatic diseases, but two rheumatologists and the American College of Rheumatology’s (ACR’s) recently updated position paper on the topic make clear that because creating and perfecting biosimilars are so difficult, taking a judicious approach makes sense.

“As we move into biosimilars in this country, we have to be extremely cautious,” says Kwas Huston, MD, a member of the ACR’s Committee on Rheumatologic Care. “We have to have the confidence that these drugs will be as effective and safe as the original drug.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The process, of course, takes time. On March 6, the U.S. Food and Drug Administration announced it had approved the first biosimilar drug, Zarxio, a cancer treatment. The potential for biosimilars for rheumatic diseases is something the ACR supports, but “decisions regarding approval of biosimilars must be driven by sound science,” the ACR’s position paper reads.

To that end, the ACR’s position highlights calls to action on both the federal and state levels. In particular, the College is calling for:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

—Rigorous clinical trials to ensure safety, efficacy and interchangeability of biosimilars with their base biologic.

—Safeguards to prevent repeated switching among biosimilars, because the potential adverse effects of switching are not yet known.

—Distinctive names for biosimilars compared with their original biologic. Names that could confuse patients or physicians make no sense and could make reporting and cataloguing of adverse effects more difficult.

—Long-term surveillance and adverse-event tracking.

“We will continue to follow the various issues surrounding the distribution, monitoring and reimbursement of biosimilars very closely as state and federal policies are proposed that affect our patients and the rheumatologists who serve them,” ACR President E. William St.Clair, MD, FACR, says in a statement. “Ensuring patients have easy access to affordable treatment options and rheumatology care continues to be a high priority for us.”

William Harvey, MD, MSc, FACR, chair of the ACR’s Committee on Government Affairs, says the path to that affordable treatment option requires more rules because it’s more complex than that of standard generics.

“Clinical trials must be rigorous and explore the impact and safety of switching in particular,” Dr. Harvey writes in an e-mail interview. “Further, all biosimilars are not exactly the same. If a typical drug is as complicated as a word of text in terms of its make-up, then a biologic (or biosimilar) is like the entire chapter of a book. Misspelling one word in that chapter means the biosimilar, while still having a similar effect, could have a different immune response. The immune system’s job is to find that one misspelled word (if it is a bacteria or virus) and attack it, so it is entirely plausible that small differences that don’t impact efficacy of the biosimilar COULD impact its immune effects.

“This is why the FDA has set a much higher bar for designating a biosimilar as ‘interchangeable.’ We are not afraid of biosimilars. We need them, and they will result, in the long term, in better access [for] patients. However, we can’t enter into that situation blindly. Testing and safeguards must be put into place.”

Taking into consideration the complexities of development, a recent Health Affairs study states that the level of cost savings achieved with biosimilars will likely be below what was expected when the Biologics Price Competition and Innovation Act was signed into law in March 2010, at least for the near future.

“The ACR has identified several key questions, several things that have to be answered to proceed,” Dr. Huston adds. “We want to make sure the right policies are in place so that physicians can feel confident and comfortable telling the patient, ‘It’s OK to be taking a biosimilar.’ Patients right now ask us all the time if it’s OK to take the generic or the brand name for drug X. Most of the time (it is), but this is different. These drugs are just not the same, and before I can tell the patient it’s OK … I need to know that everything has been done to make sure that drug is going to be effective and safe.” (posted 3/17/15)

Richard Quinn is a freelance writer in New Jersey.

 

Page: 1 2 | Multi-Page
Share: 

Filed under:Practice Support Tagged with:ACR/ARHPBiosimilarsDrugsFDApatient safetyrheumatologistTreatment

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    Biosimilars are much bigger and more complex on the molecular level than small- molecule drugs. On the right is the small-molecule structure of aspirin (21 molecules). On the left is a monoclonal antibody made up of 10,000–20,000 molecules. The various biosimilar drugs depicted include monoclonal antibodies, scFv, Fab, and scFab, whereas the small-molecule drugs are…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    paulista/shutterstock.com The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences